SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes

(2011) Ulrike Beyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The role of mutant p53 in human cancer

(2010) Amanda M Goh et al.   JOURNAL OF PATHOLOGY

Induction of TAp63 by histone deacetylase inhibitors

(2009) Berna S. Sayan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors

(2009) T. Muhlenberg et al.   CANCER RESEARCH

Mutant p53 Drives Invasion by Promoting Integrin Recycling

(2009) Patricia A.J. Muller et al.   CELL

A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis

(2009) Maddalena Adorno et al.   CELL

Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6

(2009) A. Gibbs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function Mutations

(2008) W. Yan et al.   CANCER RESEARCH

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT

Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling

(2007) Xin Yi et al.   BIOCHEMICAL PHARMACOLOGY